What Should Women Know About Compounded GLP-1 Medications for Weight Loss and Metabolic Health
Semaglutide, however, has the most mature evidence for cardiovascular risk reduction, as demonstrated in the SUSTAIN-6, PIONEER-6, and SELECT trials
Who Should Avoid It Personal or family history of medullary thyroid cancer Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Pregnancy or breastfeeding History of pancreatitis Stop Right Away If You Notice Severe persistent abdominal pain (possible pancreatitis) Persistent vomiting preventing fluid intake Signs of thyroid tumor (neck lump, hoarseness, trouble swallowing) Severe allergic reaction (rash, itching, difficulty breathing) Vision changes (possible diabetic retinopathy progression) Severe hypoglycemia (if combined with insulin/sulfonylureas) Kidney problems (decreased urination, swelling) Milder Signs to Watch For How Long Should a GLP-1 (Semaglutide) Cycle Last
In response, the salon owner told us they had not been aware they were breaking the law and would stop selling the injections
Below is a framework comparing key metabolic improvements observed in clinical trials and real-world PCOS cohorts treated with tirzepatide
Patients with conditions such as depression or eating disorders may need additional considerations before starting GLP-1 therapy